NorthWest Biotherapeutics Inc (NWBO)

[JerryCampbell]

DocLogic, I bet the results of Woodford's investigation are in the same place as the results from nwbo's "Special Litigation Committee" investigation. Of course Woodford has no fiduciary duty to report to nwbo shareholders.

Surely you remember the Committee nwbo announced via PR back in December, 2015.

"NW Bio Announces Establishment of Special Committee And Law Firm To Conduct Independent Investigation of Recent Allegations"

https://nwbio.com/nw-bio-announces-establishment-of-special-committee-and-law-firm-to-conduct-independent-investigation-of-recent-allegations/

Seems to me that Committee has never reported anything. The only mention is that the SEC is interested. From recent 10-K:

U.S. Securities and Exchange Commission


"As previously reported, the Company has received a number of formal information requests (subpoenas) from the SEC regarding several broad topics that have been previously disclosed, including the Company’s membership on Nasdaq and delisting, related party matters, the Company’s programs, internal controls, the Company’s Special Litigation Committee, disclosures and the publication of interim clinical trial data. Testimony of certain officers and third parties has been taken as well. The Company has been cooperating with the SEC investigation. As hoped, the investigation is winding to a conclusion. After investigation of a broad array of issues over the past two-plus years, the SEC Staff has informed us preliminarily that they have concerns in regard to two issues, relating to the Company’s internal controls over financial reporting and the adequacy of certain disclosures made in the past. We have previously disclosed material weaknesses in our internal controls. As for disclosures, we believe our disclosures complied with applicable law. Despite our belief that the Staff should close the investigation, there can be no assurance that the Staff will not recommend some action involving the Company and/or individuals. Given the stage of the process, the Company is unable to provide a current assessment of the potential outcome or potential liability, if any."